These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33565344)

  • 1. Serious flaws in targeting LDL-C reduction in the management of cardiovascular disease in familial hypercholesterolemia.
    Ravnskov U; de Lorgeril M; Kendrick M; Diamond DM
    Expert Rev Clin Pharmacol; 2021 Mar; 14(3):405-406. PubMed ID: 33565344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia.
    Ravnskov U; de Lorgeril M; Kendrick M; Diamond DM
    Med Hypotheses; 2018 Dec; 121():60-63. PubMed ID: 30396495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
    Rizos CV; Elisaf MS; Skoumas I; Tziomalos K; Kotsis V; Rallidis L; Garoufi A; Athyros VG; Skalidis E; Kolovou G; Koutagiar I; Papagianni M; Antza C; Katsiki N; Ganotakis E; Liberopoulos EN
    Atherosclerosis; 2018 Oct; 277():308-313. PubMed ID: 30270064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of Coagulation Factors as Critical Components of Premature Cardiovascular Disease in Familial Hypercholesterolemia.
    Ravnskov U; de Lorgeril M; Kendrick M; Diamond DM
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.
    Duell PB; Gidding SS; Andersen RL; Knickelbine T; Anderson L; Gianos E; Shrader P; Kindt I; O'Brien EC; McCann D; Hemphill LC; Ahmed CD; Martin SS; Larry JA; Ahmad ZS; Kullo IJ; Underberg JA; Guyton J; Thompson P; Wilemon K; Roe MT; Rader DJ; Cuchel M; Linton MF; Shapiro MD; Moriarty PM; Knowles JW
    Atherosclerosis; 2019 Oct; 289():85-93. PubMed ID: 31487564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein apheresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels.
    Bianconi V; Banach M; Pirro M;
    Trends Cardiovasc Med; 2021 May; 31(4):205-215. PubMed ID: 32205033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH; Santos RD
    Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Past, Present, and Future of Familial Hypercholesterolemia Management.
    Rocha VZ; Santos RD
    Methodist Debakey Cardiovasc J; 2021; 17(4):28-35. PubMed ID: 34824679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
    Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
    Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children.
    Wiegman A; Rodenburg J; de Jongh S; Defesche JC; Bakker HD; Kastelein JJ; Sijbrands EJ
    Circulation; 2003 Mar; 107(11):1473-8. PubMed ID: 12654602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of Familial Hypercholesterolemia and High Low-Density Lipoprotein Cholesterol to Ischemic Stroke: Copenhagen General Population Study.
    Beheshti S; Madsen CM; Varbo A; Benn M; Nordestgaard BG
    Circulation; 2018 Aug; 138(6):578-589. PubMed ID: 29593013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk.
    Lee S; Akioyamen LE; Aljenedil S; Rivière JB; Ruel I; Genest J
    Eur J Prev Cardiol; 2019 Aug; 26(12):1262-1270. PubMed ID: 30755017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia.
    Bogsrud MP; Græsdal A; Johansen D; Langslet G; Hovland A; Arnesen KE; Mundal LJ; Retterstøl K; Wium C; Holven KB
    J Clin Lipidol; 2019; 13(2):279-286. PubMed ID: 30910667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial Hypercholesterolemia Identification Algorithm in Patients with Acute Cardiovascular Events in A Large Hospital Electronic Database in Bulgaria: A Call for Implementation.
    Petrov I; Postadzhiyan A; Vasilev D; Kasabov R; Tokmakova M; Nikolov F; Istatkov V; Zhao B; Mutafchiev D; Petkova R
    Adv Ther; 2021 May; 38(5):2323-2338. PubMed ID: 33754300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.